Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.

MLA

Emery, Paul, et al. “Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.” PharmacoEconomics, vol. 36, no. 8, Aug. 2018, pp. 1015–27. EBSCOhost, https://doi.org/10.1007/s40273-018-0675-9.

APA

Emery, P., Van Keep, M., Beard, S., Graham, C., Miles, L., Jugl, S. M., Gunda, P., Halliday, A., & Marzo-Ortega, H. (2018). Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. PharmacoEconomics, 36(8), 1015–1027. https://doi.org/10.1007/s40273-018-0675-9

Chicago

Emery, Paul, Marjolijn Van Keep, Steve Beard, Chris Graham, LaStella Miles, Steffen Marc Jugl, Praveen Gunda, Anna Halliday, and Helena Marzo-Ortega. 2018. “Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.” PharmacoEconomics 36 (8): 1015–27. doi:10.1007/s40273-018-0675-9.